What is the appropriate management for an asymptomatic patient with aortic stenosis and a left ventricular ejection fraction of 60%?

Management of Asymptomatic Aortic Stenosis with EF 60%

In an asymptomatic patient with severe aortic stenosis and LVEF 60%, watchful waiting with close surveillance is appropriate, but you should actively look for specific high-risk features that would trigger early aortic valve replacement. 1

Initial Risk Stratification

Your first step is to determine the severity of stenosis and identify predictors of rapid progression or symptom onset:

Assess Stenosis Severity

• Very severe AS (Vmax ≥5.0 m/s or mean gradient ≥60 mmHg) → Early AVR is appropriate, especially if low surgical risk 1, 2
• Severe AS (Vmax 4.0-4.9 m/s) → Proceed to exercise testing and risk factor assessment 1

Perform Exercise Stress Testing

This is critical because many patients who claim to be asymptomatic actually have exercise limitations they've adapted to 1, 2:

• Abnormal test (symptoms develop, or systolic BP falls ≥10-20 mmHg from baseline) → AVR is indicated regardless of surgical risk 1
• Normal test → Proceed to assess progression markers 1

Decision Algorithm for Normal Exercise Test

If exercise testing is normal, your decision hinges on the presence of ≥1 predictor of rapid progression:

High-Risk Predictors Present

Look for:

• Rapid velocity progression (ΔVmax >0.3 m/s per year) with severe valve calcification 1, 2
• Markedly elevated BNP (>3× age/sex-adjusted normal, confirmed on repeat) 1, 2
• Excessive LV hypertrophy in the absence of hypertension 1

If ≥1 predictor present:

• Low surgical risk → AVR is appropriate; medical management may be appropriate 1
• High/intermediate surgical risk → AVR is appropriate; medical management may be appropriate 1

No High-Risk Predictors Present

If no predictors present:

• Medical management with surveillance is appropriate 1
• AVR may be appropriate even without predictors, given the relentless progression of severe AS 1

Special Consideration: LVEF Threshold

Critical pitfall: While your patient has LVEF 60%, emerging evidence suggests LVEF <55% is associated with significantly worse outcomes 1, 3:

• Registry data show patients with LVEF <55% have higher 5-year mortality (59% vs 72-74% for LVEF ≥55%) 1, 3
• In asymptomatic severe AS with LVEF <55%, early surgical management reduces all-cause mortality 1, 3
• LVEF 55-59% has comparable prognosis to LVEF ≥60% 1, 3

Therefore, serial monitoring of LVEF is essential—if it declines toward 55%, this should trigger intervention even if the patient remains asymptomatic 1, 3

Surveillance Protocol

For asymptomatic patients under watchful waiting:

• Clinical assessment every 6 months 1, 2
• Echocardiography every 12 months (every 6 months if borderline features like LVEF 55-60%) 1, 2
• Monitor for velocity progression ≥0.3 m/s per year—this signals disease acceleration and should prompt re-evaluation for AVR 1, 2
• Instruct patient to report any change in functional status immediately 1

Contraindicated Medical Therapies

Do not prescribe:

• Statins to slow AS progression (Class III—ineffective) 2
• Aggressive diuretics (risk of hemodynamic collapse) 2
• Vasodilators before AVR (can precipitate instability) 2

Concomitant Cardiac Surgery

If your patient requires other cardiac surgery (CABG, ascending aortic repair, other valve surgery):

• Concomitant AVR is indicated regardless of symptom status 1, 2
• Medical management is rarely appropriate in this scenario 1

Recent Evidence on Early Intervention

Emerging data favor earlier intervention in asymptomatic severe AS:

• A 2025 meta-analysis showed early AVR reduced all-cause mortality (HR 0.51) and cardiac mortality (RR 0.51) compared to conservative treatment 4
• A 2024 study demonstrated that early SAVR restores survival comparable to age-matched general population, but patients with moderate-severe LVH at surgery had worse outcomes (HR 2.32), supporting intervention before LVH develops 5
• A 2021 meta-analysis found AVR benefit across the entire LVEF spectrum in asymptomatic severe AS, questioning the need for any LVEF threshold 6

However, current guidelines still recommend watchful waiting for truly asymptomatic patients without high-risk features 1, though this may evolve as trial data mature.

Common Pitfalls to Avoid

• Missing occult symptoms: Always perform objective exercise testing—patients often unconsciously limit activity 1, 2
• Delaying intervention once LVEF declines: LVEF <55% mandates AVR even if asymptomatic 1, 3
• Ignoring rapid progression markers: ΔVmax >0.3 m/s/year signals high risk 1, 2
• Prescribing statins for AS progression: No evidence of benefit 2